GE HealthCare Technologies GEHC NASDAQ · Healthcare · United States
$83.02 +1.44% +$1.18
Summary
57 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It has been profitable 6 years in a row.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.1 USD for 1 USD of yearly profit. Over the last five years it was 18.1 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.7% a year over 5 years. Over the last 3 years it grew by 4.0% a year. For the next fiscal year analysts expect revenue to grow by 6.0%. Earnings per share grew by 2.5% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 60 USD
- Research and development 6.1 USD
- Sales and administration 21 USD
- Taxes and other 3.3 USD
- Net profit 10 USD
Net profit, industry median (Medical - Devices) 6.7 USD
Out of every 100 USD of revenue, 10 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.18%
- Paid out of profit
- 3.0%
- Raised in a row
- 1 year
You receive $0.15 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 7
- Sell 0
Today's price within the analysts' price targets
The average target of $78.8 is 5.1% below today's price. 65% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Imaging Segment 61%
- PCS Segment 20%
- PDx Segment 19%
By region
- Other Countries 46%
- UNITED STATES 44%
- CHINA 9.8%
Imaging Segment brings in 61% of revenue. PDx Segment grew fastest, by 12% a year.
Segments in detail